AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05637164
Drug: norepinephrine bitartrate
RxNorm normalized name: Norepinephrine Bitartrate
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The treatment group will receive a continuous infusion of norepinephrine at the beginning of anesthesia induction until 15 minutes after intubation. The dosage of norepinephrine was decided by the up-and-down sequential allocation method with an initial dose of 0.05 µg/kg/min and a 0.005 µg/kg/min gradient.
Trial: NCT00001028
Drug: Pentamidine isethionate
RxNorm normalized name: Pentamidine Isethionate
DrugBank: Pentamidine (DB00738)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001028
Drug: Dapsone
RxNorm normalized name: Dapsone
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05734612
Drug: Colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in the intervention group receive loading dose of colchicine 1 x 2 mg followed by colchicine 2 x 0,5 mg daily for two consecutive days.
Trial: NCT04239027
Drug: RTH258/Brolucizumab
DrugBank: Brolucizumab (DB14864)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Brolucizumab is a new generation of anti-VEGF (vascular endothelial growth factor). All patients were treated with brolucizumab 6mg: 3 loading injections (at Screening/Baseline, Week 4 and Week 8), followed by maintenance treatment every 8 weeks (Q8W) or every 12 weeks (Q12W) depending on disease activity from Week 16/Week20 to Week 40/Week 44.~Brolucizumab was administered by an intravitreal (IVT) injection to the study. eye.
Trial: NCT05606536
Drug: Crystalloid Solutions
RxNorm normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locally approved crystalloid solution will be given at the predefined infusion rate
Trial: NCT05304767
Drug: Xanomeline and Trospium Chloride Capsules
RxNorm normalized name: trospium chloride / xanomeline Pill
DrugBank: Trospium (DB00209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: KarXT 50 mg/20 mg BID KarXT 75mg/20 mg BID KarXT 100mg/20 mg BID KarXT 125mg/30 mg BID
Trial: NCT05769010
Drug: SHR-A1811
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-A1811: intravenous
Trial: NCT05769010
Drug: Pyrotinib
RxNorm normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrotinib: oral
Trial: NCT05769010
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab: intravenous
Trial: NCT06113302
Drug: Luspatercept
RxNorm normalized name: Luspatercept
DrugBank: Luspatercept (DB12281)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given by SC or (Injection)
Trial: NCT05550194
Drug: ValACYclovir 1000 MG
RxNorm normalized name: valacyclovir 1000 MG
DrugBank: Valaciclovir (DB00577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valacyclcovir is a targeted anti-viral for varicella zoster virus (VZV).
Trial: NCT05990985
Drug: Mitoxantrone hydrochloride liposome injection
RxNorm normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitoxantrone hydrochloride liposome injection (18 mg/m\^2) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle.
Trial: NCT05990985
Drug: RiTUXimab Injection
RxNorm normalized name: rituximab Injection
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: RiTUXimab Injection (375 mg/m\^2) will be administered by intravenous infusion on day 0 in a 3-week treatment cycle.
Trial: NCT05990985
Drug: Cyclophosphamid
RxNorm normalized name: Cyclophosphamid
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamid (750 mg/m\^2) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle.
Trial: NCT05990985
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vincristine (1.4 mg/m\^2，maximum dose 2mg ) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle.
Trial: NCT05146843
Drug: Mitoquinone
RxNorm normalized name: Mitoquinone
DrugBank: Mitoquinone (DB05063)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoquinone pill, 20 mg/day
Trial: NCT03763305
Drug: Propofol continuous infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol intravenous continuous infusion for anesthetic induction and maintenance
Trial: NCT03763305
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study participants receive fentanyl 1mcg/kg and propofol 1.5\~2mg/kg for induction of general anesthesia. For maintenance of anesthesia, desflurane is used to maintain 1 age-related minimum alveolar concentration (MAC).
Trial: NCT03763305
Drug: Desflurane
RxNorm normalized name: Desflurane
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 age-related minimum alveolar concentration (MAC) of desflurane inhalation for anesthetic maintenance
Trial: NCT03763305
Drug: Propofol bolus injection
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol intravenous injection for anesthetic induction
Trial: NCT04533997
Drug: Hypertonic saline solution plus intravenous furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous 60-minutes of hypertonic saline therapy plus furosemide:~Furosemide:~125 mg if home oral furosemide ≤160 mg, 250 mg if home oral furosemide \> 160 mg~Hypertonic saline solution:~Na+ 125-134: 3.4%, Na+ 135-145: 2.6%
Trial: NCT04533997
Drug: Intravenous furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous 60-minutes infusion of furosemide:~125 mg if home oral furosemide ≤ 160 mg, 250 mg if home oral furosemide \> 160 mg
Trial: NCT04969133
Drug: Levobupivacaine Hydrochloride 2.5 MG/ML
RxNorm normalized name: levobupivacaine hydrochloride 2.5 MG/ML
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To compare TAP block versus local infiltration of the trocar wounds with levobupivacaine 2.5 mg/ml for post operative pain relief after laparoscopic appendicectomy in children
Trial: NCT05881525
Drug: IL-2
RxNorm normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following cell infusion, the patient receives intravenous IL-2. IL-2 improves the survival of TC-N201 cells after infusion.
Trial: NCT05881525
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part of the non-myeloablative lymphocyte-depleting preparative regimen.
Trial: NCT05881525
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Part of the non-myeloablative lymphocyte-depleting preparative regimen.
Trial: NCT05825443
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received four 21-day cycles of chemotherapy (decided by the researcher) combined with camrelizumab (200 mg in day 1), followed by maintenance with camrelizumab (200 mg in day 1, q3w), until one year or the disease progressed or unacceptable toxicity.
Trial: NCT05499702
Drug: Hyperglycemic clamp
RxNorm normalized name: CLAMP
DrugBank: SARS-CoV-2 Sclamp (DB15849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperglycemic clamp to measure the effect of glucagon on hepatic metabolism
Trial: NCT06291116
Drug: standard care + rotigotine at 4 mg/24h for 24 months.
DrugBank: Rotigotine (DB05271)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: standard care + rotigotine at 4 mg/24h for 24 months.
Trial: NCT06395428
Drug: Haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of drug
Trial: NCT06395428
Drug: Ketorolac Tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of drug
Trial: NCT05170659
Drug: Relatlimab
RxNorm normalized name: Relatlimab
DrugBank: Relatlimab (DB14851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04483206
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05740449
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous
Trial: NCT05740449
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: oral
Trial: NCT05740449
Drug: Navitoclax
RxNorm normalized name: navitoclax
DrugBank: Navitoclax (DB12340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT05740449
Drug: intrathecal chemotherapy
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement
Trial: NCT05457933
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin 10 mg, every day before breakfast. Glargine insulin 300 Units/mL, average dose: 10-20 U/day; Insulin lispro 100 Units/mL, average dose: 10-30 U/day
Trial: NCT05457933
Drug: Glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Glargine insulin; 300 Units/mL, average dose: 10-20 U/day, Insulin lispro 100 Units/mL, average dose: 10-30 U/day
Trial: NCT04829383
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1,200 mg
Trial: NCT04829383
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 15 mg/kg
Trial: NCT04969497
Drug: Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0
DrugBank: Zolmitriptan (DB00315)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0
Trial: NCT06548997
Drug: GZR18
RxNorm normalized name: Grazoprevir
DrugBank: Grazoprevir (DB11575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 μg/kg-maximum tolerated dose (MTD), single dose or two doses
Trial: NCT04637555
Drug: sacubitril/valsartan
RxNorm normalized name: SACUBITRIL/VALSARTAN
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: LCZ696 (sacubitril/valsartan) tablet will be available in 24/26 mg, 49/51 mg and 97/103 mg, respectively
Trial: NCT05378555
Drug: Ketamine Hydrochloride
RxNorm normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients in this study will receive oral ketamine for the treatment of pain from vaso-occlusive crisis. Patients will receive 0.5 mg/kg ketamine Q8hrs for 48 hours.
Trial: NCT05035277
Drug: Apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Standard dose apixaban will be one of the options for the patients in the experimental arm.
Trial: NCT05035277
Drug: Rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Standard dose rivaroxaban will be one of the options for the patients in the experimental arm.
Trial: NCT05035277
Drug: Edoxaban
RxNorm normalized name: Edoxaban
DrugBank: Edoxaban (DB09075)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Standard dose edoxaban will be one of the options for the patients in the experimental arm.
Trial: NCT06498167
Drug: Upadacitinib
RxNorm normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Exposure to upadacitinib (Rinvoq™) in its different formulations approved by the Portuguese regulatory authority (15, 30, or 45mg extended-release tablets).
Trial: NCT03446807
Drug: Droxidopa
RxNorm normalized name: Droxidopa
DrugBank: Droxidopa (DB06262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Droxidopa in 100, 200, and 300mg capsules. Maximum dose to be used in this study is 600mg.
Trial: NCT04834973
Drug: tigilanol tiglate
RxNorm normalized name: Tigilanol Tiglate
DrugBank: Tigilanol tiglate (DB18800)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single or multiple Intratumoural treatment of tigilanol tiglate at escalating doses of 0.6 mg/m2, 1.2 mg/m2 and 2.4 mg/m2.~Tigilanol tiglate is a novel, short-chain diterpene ester in early clinical development for local treatment of a wide range of solid tumours.
Trial: NCT04834973
Drug: pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Three weekly 200 mg intravenous pembrolizumab treatment.~Pembrolizumab is a systemic anti-programmed cell death receptor 1 (PD 1) immunotherapy.
Trial: NCT04765137
Drug: Atorvastatin Oral Tablet
RxNorm normalized name: atorvastatin Oral Tablet
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin pill 40 mg to be taken every night
Trial: NCT04799236
Drug: Group 1: Miltefosine
DrugBank: Miltefosine (DB09031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Miltefosine 50 mg pill will be administered po every 8 hours with food, during 28 days
Trial: NCT04799236
Drug: Group 2: Pentavalent Antimony
DrugBank: Pentavalent Antimony (DB13047)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: will be administered by IV infusion diluted in 150 ml of DWD5% over 20 minutes
Trial: NCT04799236
Drug: Group 3: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 amps (150 mg) will be administered by IV infusion iver 2 hours every other day for a total of 15 doses.
Trial: NCT05190705
Drug: Loncastuximab Tesirine
RxNorm normalized name: Loncastuximab tesirine
DrugBank: Loncastuximab tesirine (DB16222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered by intravenous infusion
Trial: NCT05190705
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Taken orally or administered by intravenous infusion
Trial: NCT06469203
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Women undergoing dilation and curettage, who meet the eligibility criteria for the study, will be divided into two groups. They will receive the assigned medication at the beginning of the procedure, after cervical dilation but before using suction curettage.~Group 1: Participants will receive 100 ml of saline alone. Group 2: Participants will receive an intravenous infusion of 8 units of oxytocin diluted in 100 ml of saline.
Trial: NCT06469203
Drug: Sodium Chloride 0.9% Inj
RxNorm normalized name: SODIUM CHLORIDE 0.9% INJ
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Women undergoing dilation and curettage, who meet the eligibility criteria for the study, will be divided into two groups. They will receive the assigned medication at the beginning of the procedure, after cervical dilation but before using suction curettage.~Group 1: Participants will receive 100 ml of saline alone. Group 2: Participants will receive an intravenous infusion of 8 units of oxytocin diluted in 100 ml of saline.
Trial: NCT05649618
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part of the non-myeloablative lymphocyte-depleting preparative regimen
Trial: NCT05649618
Drug: IL-2
RxNorm normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following cell infusion, the patient receives high-dose bolus IL-2, which is dosed to individual patient tolerance.
Trial: NCT05825209
Drug: Food-Grown Magnesium
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 daily dose of 2 capsules equivalent to 80mg food-grown magnesium (40mg per capsule)
Trial: NCT05825209
Drug: Microcrystalline cellulose
RxNorm normalized name: Microcrystalline Cellulose
DrugBank: Microcrystalline cellulose (DB14158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 daily dose of 2 capsules containing microcrystalline cellulose
Trial: NCT05358509
Drug: Ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pregnant participants randomized to intervention arm 1 will receive a single dose of ferric carboxymaltose having 1000mg of iron if they weigh over 50kg. If a participant is under 50kg, they will receive a lower dose as determined by a formula used by the manufacturer (20mg iron/kg body weight). This will be given ideally immediately after randomization, sometime between 14 weeks and 17 weeks of pregnancy.
Trial: NCT05358509
Drug: Iron isomaltoside
RxNorm normalized name: Iron isomaltoside 1000
DrugBank: Iron isomaltoside 1000 (DB12208)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregnant participants randomized to intervention arm 1 will receive a single dose of iron isomaltoside having 1000mg of iron if they weigh over 50kg. If a participant is under 50kg, they will receive a lower dose as determined by a formula used by the manufacturer (20mg iron/kg body weight). This will be given ideally immediately after randomization, sometime between 14 weeks and 17 weeks of pregnancy.
Trial: NCT05358509
Drug: Ferric Sulfate
RxNorm normalized name: Ferric Sulfate
DrugBank: Ferric sulfate (DB11171)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pregnant participants randomized to the oral iron arm will be given 200 ferrous sulphate tablets with 60mg elemental iron each, immediately after randomization, and instructed to take two per day (one in the morning and one at night) throughout the remainder of their pregnancy.
Trial: NCT04233073
Drug: andexanet alfa
RxNorm normalized name: andexanet alfa
DrugBank: Andexanet alfa (DB14562)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Andexanet is a recombinant version of human FXa
Trial: NCT06570187
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine will be administered with an initial dose of 0.2 μg/kg/hour, infusion rate is to be titrated based on response for at least 24 hours.
Trial: NCT06570187
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol will be administered as the comparator sedative with the standard treatment of sepsis and septic shock.
Trial: NCT04809233
Drug: Tipifarnib
RxNorm normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05474690
Drug: Docetaxel + Carboplatin + Trastuzumab + Pertuzumab
RxNorm normalized name: hyaluronidase / pertuzumab / trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects who met the inclusion conditions were randomly divided into TCbHP group and ECHP-THP group according to 1:1.~Stratified at randomization by the following factors: T, N, HER2 expression (HER2 protein 3+ vs HER2 protein 2+ but FISH+), and hormone receptor status (HR positive vs HR negative).~TCbHP regimen drug dose: docetaxel 75 mg/m2 + carboplatin (AUC=6) + trastuzumab (first loading dose 8 mg/kg, sequential maintenance dose 6 mg/kg) + pertuzumab Antibiotics (the initial loading dose of 840 mg, and the sequential maintenance dose of 420 mg), every 21 days as a cycle.
Trial: NCT06569147
Drug: Elranatamab
RxNorm normalized name: ELRANATAMAB
DrugBank: Elranatamab (DB15395)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elranatamab administered subcutaneously for 6 cycles of treatment with 28 days in a treatment cycle
Trial: NCT05525338
Drug: Alectinib
RxNorm normalized name: Alectinib
DrugBank: Alectinib (DB11363)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In case of an alectinib plasmaconcentration Cmin \<435 ng/mL, determined by TDM, and manageable toxicity, the alectinib dose will be increased with 150mg BID up to a maximum of 900mg BID. In case of unacceptable toxicity (i.e. unbearable or persistent grade 2 toxicity and grade 3/4 toxicity), the alectinib dose can be reduced by 150mg BID.
Trial: NCT04709302
Drug: ART
RxNorm normalized name: MART1
DrugBank: Melanoma antigen recognized by T-cells 1 (DB15081)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients on ART
Trial: NCT05971004
Drug: Depo medrol
RxNorm normalized name: Depo-Medrol
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one injection of depo-medrol at the site of inflamed ligament attachment point (femoral condyle), combined with oral slow-acting symptomatic drugs (glucosamine 1500mg, atrodar 50mg) for 3 consecutive months.
Trial: NCT06226506
Drug: Test (T) Aprepitant injection
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specification: Aprepitant injection 4.4ml∶32mg. Produced and supplied by Qilu Pharmaceutical (Hainan) Co.
Trial: NCT06226506
Drug: Reference (R) Aprepitant injection
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specification: Aprepitant injection 4.4ml∶32mg. Produced by Heron Therapeutics, Inc and supplied by Qilu Pharmaceutical (Hainan) Co.